Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020 : an observational cohort study
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To examine the temporal patterns of patient characteristics, treatments used and outcomes associated with COVID-19 in patients who were hospitalised for the disease between January and 15 November 2020.
DESIGN: Observational cohort study.
SETTING: COVID-19 subset of the Optum deidentified electronic health records, including more than 1.8 million patients from across the USA.
PARTICIPANTS: There were 51 510 hospitalised patients who met the COVID-19 definition, with 37 617 in the laboratory positive cohort and 13 893 in the clinical cohort.
PRIMARY AND SECONDARY OUTCOME MEASURES: Incident acute clinical outcomes, including in-hospital all-cause mortality.
RESULTS: Respectively, 48% and 49% of the laboratory positive and clinical cohorts were women. The 50- 65 age group was the median age group for both cohorts. The use of antivirals and dexamethasone increased over time, fivefold and twofold, respectively, while the use of hydroxychloroquine declined by 98%. Among adult patients in the laboratory positive cohort, absolute age/sex standardised incidence proportion for in-hospital death changed by -0.036 per month (95% CI -0.042 to -0.031) from March to June 2020, but remained fairly flat from June to November, 2020 (0.001 (95% CI -0.001 to 0.003), 17.5% (660 deaths /3986 persons) in March and 10.2% (580/5137) in October); in the clinical cohort, the corresponding changes were -0.024 (95% CI -0.032 to -0.015) and 0.011 (95% CI 0.007 0.014), respectively (14.8% (175/1252) in March, 15.3% (189/1203) in October). Declines in the cumulative incidence of most acute clinical outcomes were observed in the laboratory positive cohort, but not for the clinical cohort.
CONCLUSION: The incidence of adverse clinical outcomes remains high among COVID-19 patients with clinical diagnosis only. Patients with COVID-19 entering the hospital are at elevated risk of adverse outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
BMJ open - 12(2022), 2 vom: 28. Feb., Seite e055137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Page, John H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 07.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2021-055137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337596905 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337596905 | ||
| 003 | DE-627 | ||
| 005 | 20231226204309.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2021-055137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337596905 | ||
| 035 | |a (NLM)35228287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Page, John H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020 |b an observational cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 07.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To examine the temporal patterns of patient characteristics, treatments used and outcomes associated with COVID-19 in patients who were hospitalised for the disease between January and 15 November 2020 | ||
| 520 | |a DESIGN: Observational cohort study | ||
| 520 | |a SETTING: COVID-19 subset of the Optum deidentified electronic health records, including more than 1.8 million patients from across the USA | ||
| 520 | |a PARTICIPANTS: There were 51 510 hospitalised patients who met the COVID-19 definition, with 37 617 in the laboratory positive cohort and 13 893 in the clinical cohort | ||
| 520 | |a PRIMARY AND SECONDARY OUTCOME MEASURES: Incident acute clinical outcomes, including in-hospital all-cause mortality | ||
| 520 | |a RESULTS: Respectively, 48% and 49% of the laboratory positive and clinical cohorts were women. The 50- 65 age group was the median age group for both cohorts. The use of antivirals and dexamethasone increased over time, fivefold and twofold, respectively, while the use of hydroxychloroquine declined by 98%. Among adult patients in the laboratory positive cohort, absolute age/sex standardised incidence proportion for in-hospital death changed by -0.036 per month (95% CI -0.042 to -0.031) from March to June 2020, but remained fairly flat from June to November, 2020 (0.001 (95% CI -0.001 to 0.003), 17.5% (660 deaths /3986 persons) in March and 10.2% (580/5137) in October); in the clinical cohort, the corresponding changes were -0.024 (95% CI -0.032 to -0.015) and 0.011 (95% CI 0.007 0.014), respectively (14.8% (175/1252) in March, 15.3% (189/1203) in October). Declines in the cumulative incidence of most acute clinical outcomes were observed in the laboratory positive cohort, but not for the clinical cohort | ||
| 520 | |a CONCLUSION: The incidence of adverse clinical outcomes remains high among COVID-19 patients with clinical diagnosis only. Patients with COVID-19 entering the hospital are at elevated risk of adverse outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a public health | |
| 700 | 1 | |a Londhe, Ajit A |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Sprafka, J Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Corina |e verfasserin |4 aut | |
| 700 | 1 | |a Braunlin, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Carolyn A |e verfasserin |4 aut | |
| 700 | 1 | |a Charuworn, Prista |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Alvan |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Karminder |e verfasserin |4 aut | |
| 700 | 1 | |a He, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Junjie |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Ayodele, Olulade |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Carlson, Katherine B |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Shun-Chiao |e verfasserin |4 aut | |
| 700 | 1 | |a Devercelli, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Jonsson-Funk, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Keenan, Hillary A |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Kaili |e verfasserin |4 aut | |
| 700 | 1 | |a Roehl, Kimberly A |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Luyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Zhongyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Linyun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Gondek, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Critchlow, Cathy W |e verfasserin |4 aut | |
| 700 | 1 | |a Bradbury, Brian D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 12(2022), 2 vom: 28. Feb., Seite e055137 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:2 |g day:28 |g month:02 |g pages:e055137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2021-055137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 2 |b 28 |c 02 |h e055137 | ||